Compare AbCellera Biologics Inc (ABCL) vs Super Micro Computer Inc (SMCI) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Super Micro Computer (SMCI) trades at $27.19, down 0.11% with bearish technical signals. The stock faces headwinds from a Taiwan probe into alleged AI chip smuggling, contributing to recent volatility. Fundamentally, SMCI shows strong revenue growth with $22B in 2025 and $33.7B projected for 2026, though profit margins compressed from 4.77% to 3.7%. Valuation appears attractive with P/E of 14.31 and P/S of 0.54, while recent earnings beat expectations in two of the last three quarters.

The outlook remains cautious due to regulatory risks and negative technical momentum. Analyst consensus is mixed with 36% buy ratings and a $36.43 price target suggesting 34% upside. Key risks include the ongoing Taiwan investigation, competitive pressures in AI infrastructure, and cash flow volatility with projected negative operating cash flow in 2026. The stock presents a value opportunity but requires careful risk management.